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Restriction of memory B cell differentiation at the
germinal center B cell positive selection stage
Amparo Toboso-Navasa1, Arief Gunawan1*, Giulia Morlino1*, Rinako Nakagawa1, Andrea Taddei1, Djamil Damry1, Yash Patel2,
Probir Chakravarty3, Martin Janz4, George Kassiotis2, Robert Brink5, Martin Eilers6, and Dinis Pedro Calado1,7
Memory B cells (MBCs) are key for protection from reinfection. However, it is mechanistically unclear how germinal center
(GC) B cells differentiate into MBCs. MYC is transiently induced in cells fated for GC expansion and plasma cell (PC) formation,
so-called positively selected GC B cells. We found that these cells coexpressed MYC and MIZ1 (MYC-interacting zinc-finger
protein 1 [ZBTB17]). MYC and MIZ1 are transcriptional activators; however, they form a transcriptional repressor complex
that represses MIZ1 target genes. Mice lacking MYC–MIZ1 complexes displayed impaired cell cycle entry of positively selected
GC B cells and reduced GC B cell expansion and PC formation. Notably, absence of MYC–MIZ1 complexes in positively selected
GC B cells led to a gene expression profile alike that of MBCs and increased MBC differentiation. Thus, at the GC positive
selection stage, MYC–MIZ1 complexes are required for effective GC expansion and PC formation and to restrict MBC
differentiation. We propose that MYC and MIZ1 form a module that regulates GC B cell fate.
Introduction
The germinal center (GC) is an antigen- and T cell–dependent
reaction in which B cells undergo affinity maturation and dif-
ferentiation (De Silva and Klein, 2015; Victora and Nussenzweig,
2012). In GCs, B cells cyclically migrate between an area called
the dark zone (DZ), which is enriched for proliferating cells and
where somatic hypermutation occurs, and an area called the
light zone (LZ), in which B cells retrieve antigen from follicular
(FO) dendritic cells (FDCs) through their B cell receptor (BCR)
and present that antigen to T cells (Allen et al., 2004; Kepler and
Perelson, 1993; Victora et al., 2010). T cell help, including
CD40L-CD40 engagement, positively selects a fraction (∼5–20%)
of LZ B cells, and our work and that of others showed that
positive selection critically involves induction of MYC to license
cell cycle, after which cells migrate back to the DZ, leading to GC
expansion (Calado et al., 2012; Dominguez-Sola et al., 2012;
Finkin et al., 2019; Luo et al., 2018; Schwickert et al., 2011). More
recently, it was shown that positively selected LZ B cells (LZ
MYC+ cells) are further composed of plasma cell (PC) precursors
and that these also express Myc (Ise et al., 2018).
In addition to expansion in the GC and PC differentiation, LZ
B cells also differentiate into memory B cells (MBCs). MBCs are
key for long-term protection from reinfection, but how their fate
is specified is poorly understood. MBC differentiation was
thought to be an unregulated process (Inoue et al., 2018; Smith
et al., 2000). Studies have shown, however, that MBCs have, in
general, lower antigen affinity compared with LZ B cells fated
for GC expansion and PC differentiation (De Silva and Klein,
2015; Shinnakasu et al., 2016; Weisel et al., 2016). Recently, it
was found that LZ B cells expressing high levels of the gene
encoding the transcription factor BACH2 are favored for MBC
differentiation (Shinnakasu et al., 2016) and that quiescent LZ
B cells are enriched for MBC precursors (Laidlaw et al., 2017;
Suan et al., 2017; Wang et al., 2017). MYC is critically required
for cell cycle entry of LZ MYC+ cells, and these cells are pri-
marily fated for GC expansion and PC differentiation (Calado
et al., 2012; Dominguez-Sola et al., 2012; Ise et al., 2018). We
therefore raised the question whether MYC activity in LZ MYC+
cells restricts MBC differentiation.
In human cancers, MYC and the transcription activator MIZ1
(MYC-interacting zinc-finger protein 1 [ZBTB17]) can form a
protein complex that represses the expression of MIZ1 target
genes, most notably cyclin-dependent kinase inhibitor genes
such as CDKN1A (Conacci-Sorrell et al., 2014; Peukert et al., 1997;
Wiese et al., 2013). Mechanistically, MYC displaces MIZ1
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coactivators EP300 and NPM1, converting MIZ1 from a tran-
scriptional activator to a transcriptional repressor (Staller et al.,
2001; Walz et al., 2014; Wanzel et al., 2008). Currently, the
functions of MYC–MIZ1 complexes in physiology remain un-
determined (Wiese et al., 2013). However, given that quiescent
LZ B cells are enriched for MBC precursors (Laidlaw et al., 2017;
Suan et al., 2017; Wang et al., 2017) and that MYC–MIZ1 com-
plexes regulate cell cycle, we hypothesized that MYC–MIZ1
complex activity regulates MBC differentiation.
We found that at the positive selection stage GC B cells mostly
coexpress MYC and MIZ1. The absence of MYC–MIZ1 complexes
impaired cell cycle entry of LZ MYC+ cells, reducing GC ex-
pansion in a CDKN1A-independent manner, and interfered with
PC formation. Notably, derepression of MIZ1 target genes led to
a gene expression profile (GEP) alike that of MBCs, and mice
lacking MYC–MIZ1 complexes had increased MBC differentia-
tion. We propose that the transcription factors MYC and MIZ1
form a module that regulates the fate of positively selected GC
B cells.
Results
Positively selected GC B cells mostly coexpress MYC and MIZ1
We first assessed the expression of Miz1 in GC B cell sub-
populations, including LZ MYC+ cells, using publicly available
data (Chou et al., 2016). In contrast to Myc, which was strongly
induced in LZ MYC+ cells, the expression of Miz1 in these cells
was similar to that of LZ B cells negative for MYC (LZ MYCneg
cells; Fig. S1 A). Next, we performed immunofluorescence of
spleens of wild-type mice at 10 d after immunization with sheep
RBCs (SRBCs) and delineated GCs (IgDneg), DZ and LZ (FDC de-
pleted and enriched, respectively), and MYC expression to
identify positively selected GC B cells. We found MIZ1 to be
mostly coexpressed with MYC (Fig. 1, A and B). Collectively,
these data indicated that MIZ1 expression is primarily regulated
at a posttranscriptional level. MYC expression in GC B cells is
synergistically induced by BCR and CD40 coengagement (Fig. S1
B; Luo et al., 2018). However, we found that BCR and CD40
coengagement was insufficient to induce MIZ1 expression in GC
B cells stimulated in vitro (Fig. S1, C and D). Thus, althoughMYC
and MIZ1 coexpression occurs in LZ MYC+ cells, the require-
ments for their induction are not identical.
MIZ1 target genes are up-regulated in the absence of
MYC–MIZ1 complexes
To investigate if MIZ1 target genes are regulated by MYC–MIZ1
complexes in positively selected GC B cells, we used a genetically
modified mouse strain (MycVD) that carries a MYC mutant en-
coded at the endogenous Myc locus (Herold et al., 2002; Saba
et al., 2011). In these mice, replacement of a valine at position
394 by aspartic acid (V394D, MycVD) abrogates MYC–MIZ1 in-
teraction without interfering with the binding of MYC to its
obligatory partner, MAX, and hence MYC transcriptional acti-
vation (Fig. 2 A; Herold et al., 2002; Saba et al., 2011; Walz et al.,
2014). We first investigated the expression of MYC in MycVD.
We immunized MycVD and wild-type mice (MycWT) with SRBC
and determined 10 d later the fraction of LZ MYC+ cells using
intracellular stain and flow cytometry. MycVD contained a slight
but significantly increased fraction of LZ MYC+ cells compared
with MycWT (Fig. 2, B and C), whereas MYC expression levels
were identical between genotypes (Fig. 2 D). Thus, the absence
of MYC–MIZ1 complexes did not impair the induction of MYC
nor its expression level.
To investigate if the absence of MYC–MIZ1 complexes altered
gene expression we FACS-purified LZ B cells of MycVD and
MycWT and performed RNA sequencing (RNA-seq) followed by
bioinformatic analysis. We first asked whether the GEP of LZ
MYC+ cells was altered in the absence of MYC–MIZ1 complexes.
For that, we used publicly available RNA-seq datasets (Chou
et al., 2016) and generated signatures of genes down-regulated
(LZ MYC+ vs. LZ MYCneg DOWN) or up-regulated (LZ MYC+ vs. LZ
MYCneg UP) in LZ MYC+ compared with LZ MYCneg cells. Using
gene set enrichment analysis (GSEA), we found that the MycVD
LZ GEP was significantly enriched for the “LZ MYC+ vs. LZ
MYCneg DOWN” gene signature and that the MycWT LZ GEP was
significantly enriched for the “LZ MYC+ vs. LZ MYCneg UP” gene
signature (Fig. 2 E). These data indicated that the absence of
MYC–MIZ1 complexes in LZMYC+ cells profoundly altered their
GEP, possibly due to the up-regulation of MIZ1 target genes
repressed by MYC–MIZ1 complexes in those cells.
To identify differentially expressed genes between LZMycVD
and LZ MycWT that are direct targets of MYC–MIZ1 complexes,
we generated and analyzed MYC and MIZ1 chromatin immu-
noprecipitation sequencing (ChIP-seq) in mouse B cells. In
agreement with the absence of the repressive activity of MYC–
MIZ1 complexes, the LZ MycVD GEP was significantly enriched
for the expression of MIZ1 target genes that are bound by MYC
compared withMycWT (Fig. 2 F). We found 60MIZ1 target genes
bound by MYC that were significantly up-regulated in the LZ
of MycVD compared with that of MycWT (Fig. S1 E). A fraction
of these genes (21 genes) enriched for the Gene Ontology (GO)
biological processes related to signal transduction, response
to stress, homeostasis, and gene expression (Fig. 2 G). These
included genes encoding known tumor suppressors, namely
Arhgef1, a RhoA-specific guanine nucleotide exchange factor
frequently lost in GC B cell–derived lymphomas (Muppidi et al.,
2014); the cytokine-regulated Gadd45g, required in hematopoi-
etic stem cell differentiation and lineage selection (Lu et al.,
2001; Thalheimer et al., 2014); and the U3 ubiquitin ligase
Sh2b3 that regulates JAK2 stability, which is frequently lost in
acute lymphoblastic leukemia (Lv et al., 2017; Perez-Garcia et al.,
2013). Genes involved in signal transduction included Itpr1, a
Ca2+ channel required for normal B cell development and
function (Tang et al., 2017); Map2k7, which directly activates
c-JUN and is known to have an antiproliferative activity in
B cells (Sasaki et al., 2001; Tournier et al., 1997); the AKT sub-
strate Akt1s1, which negatively regulates mTOR activity (Sancak
et al., 2007); and Vav2, which is critical for humoral immune
responses and B cell maturation (Doody et al., 2001). Genes in-
volved in gene expression includedMyh9, which regulates BCR-
mediated antigen acquisition and B cell activation (Hoogeboom
et al., 2018); and multiple transcription factors, including Bcl11a,
which is essential for B cell development and repressed by
BLIMP1 during PC differentiation (Minnich et al., 2016; Yu et al.,
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2012); Rela, which was shown to be required for GC-derived PC
formation andmore recently also for MBC differentiation (Heise
et al., 2014; Koike et al., 2019); and Mafk, which encodes for the
transcription factor MAFK with which BACH2 heterodimerizes
to bind target genes in B cells (Huang et al., 2014; Oyake et al.,
1996). In summary, we found increased expression of multiple
MIZ1 target genes in the absence of MYC–MIZ1 complexes.
These data, together with the described expression pattern of
MYC and MIZ1 (Fig. 1), supported a role for MYC–MIZ1 com-
plexes in LZ MYC+ cells.
MYC–MIZ1 complexes are required for cell cycle entry of LZ
B cells
We next tested whether MYC–MIZ1 complexes have a role in the
GC reaction at the cell population level. MycVD had smaller
spleens compared with MycWT; however, the proportion of
mature B cells was identical between genotypes (Fig. S1 F). 10 d
after SRBC immunization, we observed a significant reduction
in the fraction and number of GC B cells in MycVD compared
with MycWT (Fig. 3, A and B). Histological analysis showed a
significant reduction in the size of GC clusters in MycVD com-
pared with MycWT (Fig. 3, C and D). However, the number of GC
foci was identical between genotypes (Fig. 3 D). We also ob-
served a small but significant increase in the LZ/DZ proportion
in MycVD compared with MycWT (Fig. 3, E and F), whereas the
proportion of IgG1- and IgM-expressing GC B cells was similar
between genotypes (Fig. S1 F). These data showed that MYC–
MIZ1 complexes were required for GC expansion, but not GC
formation. In agreement, analysis of an earlier time-point after
SRBC immunization (day 5), when GC clusters are formed but
before massive expansion (Calado et al., 2012), MycVD and
MycWT displayed a similar fraction of GC B cells (Fig. 3 G). In
accordance with the knowledge that LZ MYC+ cells contain PC
precursors we found a reduced fraction and number of PCs in
MycVD, which was proportional to the reduction observed for GC
B cells (Fig. S1, G–I). These phenotypes did not seem to arise
because of impaired T cell help. First, MYC expression levels,
which are in part regulated by CD40 signaling (Luo et al., 2018),
were similar between genotypes (Fig. 2, B–D). Second, the
number of PD1high CXCR5high CD4+ T cells, which mostly rep-
resents GC T FO helper cells (Tfh cells), was proportional to that
of GC B cells in MycVD and MycWT (Fig. S1, J and K). And third,
genes up-regulated by CD40 signaling were found to be enriched
in the MycVD LZ GEP compared with MycWT (Fig. S1 L).
We next tested whether absence of MYC–MIZ1 complexes
had an impact on the survival of GC B cells. However, we did not
observe statistically significant differences in apoptosis between
genotypes, although a trend toward a reduced fraction of active
caspase 3+ cells was noticeable in the LZ of MycVD compared
with MycWT (Fig. 3 H). Suggesting an altered cell cycle profile,
GSEA of the GO term “CELL_CYCLE_ARREST” gene signature
revealed a significant enrichment in the MycVD LZ GEP com-
pared with MycWT, whereas, in contrast, the GO term “G1-
S_PHASE_TRANSITION” gene signature was enriched inMycWT
LZ GEP compared with MycVD (Fig. 3 I). To determine whether
the activity of MYC–MIZ1 complexes was required for the cell
Figure 1. Positively selected GC B cells mostly coex-
press MYC and MIZ1. (A) Representative confocal immu-
nofluorescence of a splenic GC at day 10 (D10) after SRBC
immunization (SRBCi) in a wild-type C57BL/6 mouse (MIZ1,
red; MYC, green; IgD, white; and FDC/CD35, cyan). Lines
delineate GC and LZ/DZ borders. Scale bars, 30 µm.
(B)Quantification of the fraction of double-positiveMIZ1+MYC+
and MIZ1+, MYC+ single-positive cells in the LZ (top) and DZ
(bottom), stained as in A. Each symbol (B) represents an indi-
vidual GC; small horizontal lines show median, minimum, and
maximum values. Data in B are representative of three inde-
pendent experiments (three mice, and approximately two GCs
per mouse/per experiment). **, P ≤ 0.01 (unpaired two-tailed
Student’s t test).
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cycle of GC B cells, we performed 5-ethynyl-29-deoxyuridine
(EdU) pulse experiments. We found impaired cell cycle en-
gagement of MycVD LZ B cells compared with MycWT, whereas
the fraction of DZ B cells engaged in cell cycle was identical
between genotypes (Fig. 3, J and K). The cell cycle defect was not
due to altered mTORC1 activity (Ersching et al., 2017), as LZ
MYC+ cells of MycVD and MycWT displayed similar levels of
phospho-S6 kinase (Fig. 3, L and M). We also did not observe
altered expression of cyclin genes Ccnd2 (a target of MYC;
Bouchard et al., 1999; Calado et al., 2012) and Ccnd3 in the ab-
sence of MYC–MIZ1 complexes (Cato et al., 2011; Peled et al.,
2010; Fig. S2 A). Notably, the expression of the MIZ1 target
genes Cdkn1a, Cdkn2a, and Cdkn2b, known to be repressed by
MYC–MIZ1 complexes in cancer cells (Walz et al., 2014), were
also similar between the LZ of MycVD and MycWT (Fig. S2 B). In
agreement, ablation of Cdkn1a was insufficient to rescue the
MycVD phenotype (Fig. 4, A–D), including the cell cycle defect of
LZ B cells (Fig. 4 E). The expression of Cdkn1b was, however,
increased in the LZ of MycVD compared with that of MycWT (Fig.
S2 C), but neither we (Fig. S1 E) nor others (Walz et al., 2014)
identified Cdkn1b as a direct MIZ1 target.
We next asked if the absence of MYC–MIZ1 complexes sim-
ilarly altered the cell cycle of non-GC B cells in vitro. We first
tested whether stimulation of naive B cells, including BCR and
CD40 coengagement, induced MIZ1. Whereas MYC expression
was already increased at 4 h after stimuli (Luo et al., 2018), MIZ1
expression was only increased after 16 h (Fig. S2, D and E). The
absence of MYC–MIZ1 complexes did not significantly impact
cell proliferation of in vitro–activated naive cells (Fig. S2 F). We
next determined the expression of MYC and MIZ1 at the very
early stages of the (pre-)GC reaction. Contrary to positively se-
lected B cells in mature GCs, coexpression of MYC andMIZ1 was
seldom observed in (pre-)GC B cells (Fig. S2, G–I). Overall these
data indicated that the requirements for MIZ1 induction varied
according to B cell stage and that MYC–MIZ1 complexes played a
function in GC B cell expansion rather than formation. Specifi-
cally, in LZ MYC+ cells the absence of MYC–MIZ1 complexes
dissociated MYC expression from cell cycle engagement.
MIZ1 target genes are enriched in MBCs
The impaired cell cycle engagement of LZ MYC+ cells of MycVD
and the knowledge that MBC precursors are found within qui-
escent LZ B cells (Laidlaw et al., 2017; Suan et al., 2017; Wang
et al., 2017) led us to investigated if the LZ MycVD GEP displayed
a shift toward that of MBCs. We first generated an MBC GEP by
performing RNA-seq of FACS-purified MBCs from day 10 SRBC-
immunized wild-type mice. Using these data, we generated
signatures of genes up-regulated (MBC vs. LZ UP) or down-
regulated (MBC vs. LZ DOWN) in MBCs compared with LZ
B cells. We found that the LZ MycVD GEP was significantly en-
riched for the “MBC vs. LZ UP” gene signature, whereas the LZ
MycWT GEP was significantly enriched for the “MBC vs. LZ
Figure 2. MIZ1 target genes are up-regulated in the absence of MYC–MIZ1 complexes. (A) Schematic representation of MYC–MIZ1 complexes. The
V394D mutation in MYC abrogates the protein–protein interaction with MIZ1, but not with MAX. (B) Intracellular staining for MYC in splenic LZ GC B cells of
MycWT and MycVD at day 10 after SRBC immunization (SRBCi). spl, spleen. (C) Cumulative data of the fraction of MYC+ cells in splenic LZ of MycWT and MycVD,
analyzed as in B. (D) Cumulative data of mean fluorescence intensity (MFI) in splenic LZ of MycWT andMycVD, analyzed as in B. (E) Bar graph displaying GSEA of
gene signature “LZMYC+ vs. LZMYCneg DOWN” and “LZMYC+ vs. LZMYCneg UP” enrichment in the GEP of LZ B cells of MycWT andMycVD. FDR, false discovery
rate; NES, normalized enrichment score. (F) Bar graph displaying normalized enrichment score of MycVD and MycWT LZ B cells GEP for genes bound in their
promoters by MIZ1 and MYC “MIZ1↔MYC” as determined by ChIP-Seq in mouse B cells. (G) Graphical representation of enrichment of GO biological processes
(GO_BP) within up-regulated genes in the LZ B cells of MycVD compared with MycWT with promoters bound by MIZ1 and MYC “MIZ1↔MYC”. Each symbol
(C: MycWT n = 14, MycVD n = 14; D: MycWT n = 10, MycVD n = 10) represents an individual mouse; small horizontal lines are median, minimum, and
maximum values. *, P ≤ 0.05 (unpaired two-tailed Student’s t test). Data in C and D are representative of three independent experiments. ns, not significant.
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Figure 3. MYC–MIZ1 complexes are required for cell cycle entry of LZ B cells. (A) Representative flow cytometry of splenic GC B cells of MycWT andMycVD
at day 10 after SRBC immunization (SRBCi). spl, spleen. (B) Cumulative data of MycWT and MycVD analyzed as in A before (day 0) and at day 10 after SRBC
immunization. Left: Fraction of GC B cells within B cells. Right: Absolute cell number of GC B cells. (C) Representative histology of MycWT and MycVD at day 10
after SRBC immunization. PNA is used as GCmarker, counterstained with hematoxylin. Scale bars, 500 µm. spl, spleen. (D) Top: Cumulative data of the area of
each GC of MycWT andMycVD, analyzed as in C. Bottom: Number of GC foci per spleen section analyzed as in C. (E) Representative flow cytometry of splenic DZ
and LZ distribution within GC B cells at day 10 after SRBC immunization. (F) Cumulative data analyzed as in E and presented as LZ/DZ ratio. (G) Kinetics of the
GC reaction and cumulative data of FACS analyses of splenic GC B cells of MycWT and MycVD at day 5 and day 10 after SRBC immunization, gated as in A.
(H) Cumulative data of active caspase 3+ GC B cells within DZ (top) or LZ (bottom) of MycWT and MycVD at day 10 after SRBC immunization. (I) Bar graph
displaying GSEA of gene signature “CELL_CYCLE_ARREST” and “G1_S_PHASE_TRANSITION” enrichment in the GEP of LZ B cells of MycWT and MycVD. FDR,
false discovery rate; NES, normalized enrichment score. (J) Flow cytometry of MycWT and MycVD at day 10 after SRBC immunization for the analysis of EdU
incorporation in the DZ (left) and LZ (right). (K) Cumulative data for EdU incorporation in DZ (left) and LZ (right). Analyzed as in J. (L) Intracellular staining for
phospho-S6 kinase (pS6K) in splenic non-GC (N-GC) B cells and MYC+, MYCneg GC B cells (GCMYC+ and GCMYCneg, respectively) of MycWT and MycVD at day 10
after SRBC immunization. (M) Cumulative data of phospho-S6 kinase mean fluorescence intensity (MFI) in MYC+ GC B cells (GCMYC+) splenic LZ of MycWT and
MycVD, analyzed as in L. Each symbol (B: day 0 MycWT n = 5, MycVD n = 5; day 10 MycWT n = 14, MycVD n = 14; F: MycWT n = 10, MycVD n = 10; H MycWT n = 12,
MycVD n = 12; K: MycWT n = 9, MycVD n = 9; M: MycWT n = 7, MycVD n = 7) represents an individual mouse; small horizontal lines show median, minimum, and
maximum values. Each symbol represents an individual GC (D) or mean and SEM (G). **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001 (unpaired two-tailed
Student’s t test). Data are representative of two (B: days 0; G: day 5; and M) or three (B: day 10; D, F, H, and K) independent experiments. ns, not significant.
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DOWN” gene signature (Fig. 5 A). To investigate whether this
enrichment was the consequence of decreased cell cycle activity
in the MycVD LZ we performed RNA-seq of FACS-purified FO
B cells, known to be quiescent, and generated signatures of
genes up-regulated (MBC vs. FO UP) or down-regulated (MBC vs.
FO DOWN) in MBCs compared FO B cells. Similar to the previous
analysis, we found that the MycVD LZ GEP was significantly
enriched for the “MBC vs. FO UP” gene signature, whereas the LZ
MycWT GEP was significantly enriched for the “MBC vs. FO
DOWN” gene signature (Fig. 5 A). Identical results were observed
when analyzing “MBC vs. FO” signatures using GEP datasets
generated by others (Fig. S3 A), in agreement with the signifi-
cant overlap between the MBC GEP generated in this work and
that of others (Fig. S3 B; Kaji et al., 2012; Weisel et al., 2016). We
also found a significant enrichment in the MycVD LZ GEP for
genes up-regulated in MBC vs. GC B cells of human origin (hu-
manMBC vs. GC_UP), whereas the MycWT LZ GEP was enriched
for genes down-regulated inMBC vs. GC B cells (humanMBC vs.
GC_DOWN; Fig. 5 B; Luckey et al., 2006). To further validate our
analysis, we used a publicly available RNA-seq dataset com-
paring LZ B cells expressing high Bach2 levels (LZ Bach2hi) that
are enriched for MBC precursors and LZ B cells expressing low
Bach2 levels (LZ Bach2low) that are enriched for cells fated for GC
expansion and PC differentiation (Shinnakasu et al., 2016). We
found that the MycWT LZ GEP was significantly enriched for the
gene signature “LZ Bach2hi vs. LZ Bach2low DOWN” that is asso-
ciated with GC expansion and PC fates (Fig. 5 A). In contrast,
MycVD LZ GEP was significantly enriched for the gene signature
“LZ Bach2hi vs. LZ Bach2low UP” that is associated with MBC
precursors (Fig. 5 A). In agreement with Bach2 levels being
down-regulated by T cell help (Shinnakasu et al., 2016), we
found that the expression of Bach2 was significantly reduced in
LZ MYC+ compared with LZ MYCneg cell subsets of wild-type
mice (Fig. S3 C). However, Bach2 levels were not different be-
tween LZ B cells of MycVD and MycWT (Fig. S3 D), further sug-
gesting that CD40 signaling is not impaired in MycVD compared
with MycWT. Overall, these analyses indicate that the absence of
MYC–MIZ1 complexes in LZ MYC+ cells altered the GEP of LZ
B cells in part through the enrichment of genes expressed
in MBCs.
Next, we investigated whether the identified 60 MIZ1 target
genes bound by MYC and significantly up-regulated in the LZ of
MycVD compared with that of MycWT (Fig. 2 G and Fig. S1 E)
were enriched in the MBC GEP. 41 out of the 60 MIZ1 target
genes (68%) had increased expression in MBCs vs. LZ B cells
(Fig. 5, C and D), and the majority of these 41 genes (30/41, 73%)
had reduced expression in LZ MYC+ compared with LZ MYCneg
cells (Fig. S3 D). These data reflected the repressive activity of
MYC–MIZ1 complexes in LZ MYC+ cells and that these com-
plexes directly repressed genes enriched in MBCs.
MYC–MIZ1 complexes restrict MBC differentiation
To assess whether MBC formation was altered in the absence of
MYC–MIZ1 complexes, we initially immunized MycVD and
MycWT with SRBC (Fig. 6 A). The fraction of IgM+ CD273+ MBCs
within B cells was significantly increased in MycVD compared
with MycWT at day 10 after SRBC immunization, albeit the ab-
solute cell number not being statistically different between
genotypes (Fig. 6 B). Nevertheless, considering that MycVD had
reduced GC B cell numbers compared with MycWT, a signifi-
cantly increased IgM+ CD273+ MBC to IgM+ GC B cell ratio was
observed, indicating that MycVD produced more IgM+ CD273+
MBCs than MycWT (Fig. 6 B). The fraction of IgG1+ CD273+ MBCs
within B cells was significantly increased at day 5 after immu-
nization in MycVD compared with MycWT, but only a trend in
terms of absolute cell numbers was observed (Fig. 6 C). How-
ever, at day 10 after SRBC immunization, the difference was
clear, as both the fraction within B cells and the absolute number
of IgG1+ CD273+ MBCs were significantly increased in MycVD
compared with MycWT (Fig. 6 C). We concluded that the absence
of MYC–MIZ1 complexes in LZ MYC+ cells increased MBC
differentiation.
It is acknowledged that MBCs can be generated by both GC-
dependent and GC-independent paths (Blink et al., 2005; Chan
Figure 4. Cdkn1a ablation does not rescue cell cycle entry of LZ B cells in
the absence of MYC–MIZ1 complexes. (A) Representative flow cytometry
of splenic GC B cells of p21KO (Cdkn1a KO) and MycVD p21KO mice at day 10
after SRBC immunization (SRBCi). spl, spleen. (B) Cumulative data of the
fraction (top) and absolute cell number (bottom) of splenic GC B cells of
p21KO and MycVD p21KO. Analyzed as in A. (C) Representative flow cytom-
etry of splenic DZ and LZ B cells of p21KO and of MycVD p21KO at day 10 after
SRBC immunization. (D) Cumulative data of active caspase 3+ splenic GC
B cells in DZ (left) and LZ (right) of p21KO and MycVD p21KO at day 10 after
SRBC immunization. (E) Cumulative data for EdU incorporation in DZ (left)
and LZ (right) of p21KO andMycVD p21KO at day 10 after SRBC immunization.
Each symbol (B: p21KO n = 7, MycVD p21KO n = 11; D: p21KO n = 3, MycVD
p21KO n = 6; and E: p21KO n = 3, MycVD p21KO n = 5) represents an individual
mouse; small horizontal lines show median, minimum, and maximum values.
****, P ≤ 0.0001 (unpaired two-tailed Student’s t test). Data are represen-
tative of two (B, D, and H) independent experiments. ns, not significant.
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et al., 2009; Good-Jacobson and Tarlinton, 2012; Inamine et al.,
2005; Takemori et al., 2014; Toyama et al., 2002). We therefore
investigated the kinetics of MBC differentiation in MycVD and
MycWT by performing EdU pulse-chase experiments in which
“3-d labeling windows” are generated through EdU injection at
specific time points after immunization (Weisel et al., 2016). The
labeling windows chosen with respect to the immunization time
point were: (1) days 0–2, which encompass the earlier stage of
the GC reaction; (2) days 5–7, which encompasses critical time
points of GC expansion; and (3) days 12–14 for a later GC stage
(Calado et al., 2012). In these experiments, analysis of mice at
day 15 after SRBC immunization revealed a significantly in-
creased number of EdU+ IgM+ CD273+ MBCs and to a greater
degree for EdU+ IgG1+ CD273+ MBCs in MycVD compared with
MycWT at the day 5–7 labeling window (Fig. 6, D and E). These
data showed that the absence of MYC–MIZ1 complexes in LZ
MYC+ cells originated a marked increase of MBC formation at
critical time points of GC expansion. We also found that the
fraction of IgG1+ LZ B cells of MycVD was significantly enriched
for cells expressing the MBC precursor marker CCR6 (Suan
et al., 2017) compared MycWT (Fig. 6, F and G), whereas the
fraction of CCR6+ cells within IgG1+ CD273+ MBCs was identical
between genotypes (Fig. 6, H and I). These data indicated that
MBC precursors were significantly increased within IgG1+ LZ
B cells of MycVD compared MycWT. Previous work in which GC
B cell formation was abrogated demonstrated that the expres-
sion of CD73 marks GC-derived MBCs, whereas MBCs lacking
CD73 can be of either GC or non-GC origin (Anderson et al.,
2007; Kaji et al., 2012; Taylor et al., 2012). We found that
∼45% of the IgM+ CD273+ MBCs generated in MycVD were CD73+
compared with∼50% inMycWT (Fig. 6 J), whereas∼40% of IgG1+
CD273+ MBCs in MycVD were CD73+ compared with ∼35% in
MycWT (Fig. 6 K). These data indicated a similar origin of MBCs
between genotypes, and we concluded that the increase in MBC
differentiation observed in the absence ofMYC–MIZ1 complexes
occurred primarily through a GC-dependent path. We also in-
vestigated the distribution of known MBC surface marker
combinations (Anderson et al., 2007; Tomayko et al., 2010)
within IgG1+ MBCs in MycVD compared with MycWT (Fig. S3,
E–H). We found significantly increased fractions of
CD73+CD80neg and CD80negCD35+ MBCs in MycVD, whereas a
decreased fraction of CD80+CD35neg was observed in these mice
(Fig. S3, F–H). Expression of CD80 was previously associated
with a higher number of somatic mutations in the IgH variable
region, whereas that of CD35 with reduced mutational load
(Anderson et al., 2007). These data therefore indicated that the
enlarged IgG1+ MBC pool of MycVD is composed of cells with
lower affinity toward the antigen, consistent with increased
MBC differentiation at critical time points of GC expansion
(Fig. 6 E), when GC antigen affinity is likely to be low.
Reduced affinity of the MBC pool in the absence of MYC–MIZ1
complexes
Following the analysis using SRBC immunization, we wanted to
determine whether the absence of MYC–MIZ1 complexes im-
pacted antigen affinity maturation. To study BCR antigen af-
finity, we generated compound mutant MycVD and MycWT
carrying the SWHEL allelic system, in which B cells express a
transgenic BCR recognizing hen egg lysozyme (HEL; Phan et al.,
2003). In this system, the BCR affinity to HEL is very high (2 ×
1010 M−1), but affinity maturation can be studied by immunizing
mice with a mutant version of HEL called HEL3X, for which
SWHEL BCR has much lower affinity (1.5 × 106 M−1; Paus et al.,
2006). According to established protocols (Paus et al., 2006), we
Figure 5. MIZ1 target genes are enriched in MBCs. (A) Bar graph displaying GSEA of gene signature “LZ Bach2hi vs. LZ Bach2low UP” and “LZ Bach2hi vs. LZ
Bach2low DOWN”; “MBC vs. LZ UP” and “MBC vs. LZ DOWN”; “MBC vs. FO UP” and “MBC vs. FO DOWN” enrichment in the GEP of LZ B cells of MycWT and
MycVD. FDR, false discovery rate; NES, normalized enrichment score. (B) GSEA of GEP of LZ B cells of MycWT and MycVD for “(human) MBC vs. GC_UP” gene
signature (left) and “(human) MBC vs. GC_DOWN” (right). (C) GSEA of GEP of MBC and LZ B cells using a gene signature composed of genes bound in their
promoters by MIZ1 and MYC “MIZ1↔MYC” and up-regulated in LZ B cells of MycVD compared with that of MycWT, as determined by ChIP-seq in mouse B cells.
(D) Graphical representation of enrichment of GO biological processes (GO_BP) within up-regulated genes in LZ B cells of MycVD compared with MycWT that
are targets of MIZ1 bound by MYC and enriched in MBCs.
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purified B cells from MycVDSWHEL and control MycWTSWHEL
and transferred them into congenic CD45.1 mice, after which
recipient mice were immunized with HEL3X (Fig. 7 A). We found
at all time points of analysis (days 8, 10, and 15) a reduction in GC
B cells and an increase of CD273+ MBCs within B cells derived
fromMycVDSWHEL compared with MycWTSWHEL (Fig. 7, B–D).
These data reproduced the phenotypes observed inMycVD (Fig. 3
and Fig. 6) and demonstrated that the reduced GC expansion and
Figure 6. MYC–MIZ1 complexes restrict MBC differentiation. (A) Representative flow cytometry gating strategy for splenic IgM+ and IgG1+ MBCs (B220+
CD19+ CD38high IgDlow CD273+) of MycWT and MycVD at day 10 after SRBC immunization (SRBCi). spl, spleen. (B) Cumulative data for splenic IgM+ CD273+
MBCs analyzed as in A at days 0, 5, and 10 after SRBC immunization. Top: Fraction of cells within B cells. Middle: Absolute cell number. Bottom: Ratio of
IgM+ CD273+ MBCs over IgM+ GC B cells. (C) Cumulative data for splenic IgG1+ CD273+ MBCs analyzed as in A at days 0, 5, and 10 after SRBC immunization.
Top: Fraction of cells within B cells. Middle: Absolute cell number. Bottom: Ratio of IgG1+ CD273+ MBCs over IgG1+ GC B cells. (D and E) Kinetics of splenic
IgM+ CD273+ (D) and IgG1+ CD273+ (E) MBC production determined by EdU pulse-chase experiments at the indicated labeling windows. Cumulative FACS
analyses of splenic MBCs analyzed as in A at day 15 after SRBC immunization (SRBCi). (F) Representative flow cytometry of CD23 and CCR6 expression within
splenic IgG1+ LZ B cells of MycWT and MycVD at day 10 after SRBC immunization. (G) Cumulative data for the fraction of CD23+ CCR6+ within splenic IgG1+ LZ
B cells from MycWT and MycVD, analyzed as in F. (H) Representative flow cytometry of CD23 and CCR6 expression within splenic IgG1+ CD273+ MBCs of MycWT
and MycVD at day 10 after SRBC immunization. (I) Cumulative data for the fraction of CD23+ CCR6+ within splenic IgG1+ CD273+ MBCs from MycWT and MycVD,
analyzed as in H. (J) Cumulative data for the fraction of CD73+ cells within splenic IgM+ CD273+ MBCs analyzed as in A at day 10 after SRBC immunization.
(K) Cumulative data for the fraction of CD73+ cells within splenic IgG1+ CD273+ MBCs analyzed as in A at day 10 after SRBC immunization. Each symbol (B and C:
day 0 MycWT n = 5, MycVD n = 4; day 5 MycWT n = 4, MycVD n = 4; day 10 MycWT n = 22, MycVD n = 19; G and I: MycWT n = 15, MycVD n = 16; J and K: MycWT n = 5,
MycVD n = 5) represents an individual mouse; small horizontal lines showmedian, minimum, andmaximum values or mean and SEM (D and E). *, P ≤ 0.05; **, P ≤
0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001 (unpaired two-tailed Student’s t test). Data are representative of two (B and C at days 0 and 5; D and E) or three (B and C at
day 10; G–K) independent experiments. ns, not significant.
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increased MBC differentiation was due to the specific absence of
MYC–MIZ1 complexes in B cells.
To determine the BCR somatic mutation pattern and affinity
maturation to HEL3X, we FACS-purified GC cells and MBCs at
day 8 and 15 after HEL3X immunization, followed by cloning and
sequencing of the IgH variable region. The replacement of a
tyrosine at position 53 to aspartic acid in SWHEL IgH (Y53D)
leads to ∼100-fold increased affinity for HEL3X (Phan et al.,
2003). At day 8 after HEL3X immunization, ∼9% of MycVDS-
WHEL GC B cells had the Y53D amino acid change compared
with ∼24% of MycWTSWHEL cells (Fig. 7 E and Fig. S4 A). The
average number of amino acid substitutions was also reduced in
MycVDSWHEL GC B cells (average, 1.6/sequence) compared with
MycWTSWHEL (average, 2.1/sequence; Fig. S4, A–C). However,
the number of nucleotide mutations in the SWHEL IgH of GC
B cells was similar between genotypes (Fig. S4 D), suggesting
that somatic hypermutation per se was not impaired. The
observed differences in GC B cells at day 8 were nevertheless
transient given that at day 15 after HEL3X immunization no
significant differences were found between genotypes (Fig. 7,
E–G; and Fig. S4, A–C). MBCs at day 8 after HEL3X immuniza-
tion of either genotype did not display Y53D mutations (Fig. 7 H
and Fig. S4 E). However, the average number of amino acid
substitutions was lower in MycVDSWHEL MBCs (average, 1/se-
quence) compared with MycWTSWHEL (average, 1.4/sequence;
Fig. S4, E–G). Still, only small differences were found with re-
spect to nucleotide mutations, with ∼80% of MycVDSWHEL
MBCs carrying a somatically mutated BCR compared with ∼85%
of MycWTSWHEL MBCs (Fig. S4 H). At day 15 of analysis, the
absence of MYC–MIZ1 complexes significantly impacted BCR
antigen affinity of MBCs, with ∼60% of MycVDSWHEL MBCs
cells carrying Y53D mutations compared with ∼87% of
MycWTSWHEL cells (Fig. 7 H and Fig. S4 E). This was accom-
panied by a reduced number of amino acid substitutions in
Figure 7. Reduced affinity of the MBC pool in the absence of MYC–MIZ1 complexes. (A) Experimental design. (B) Kinetics of GC B cells within splenic
CD45.2+ donor cells at days 8, 10, and 15 after HEL3X immunization. (C) Kinetics of CD273+ MBCs within splenic CD45.2+ donor cells at days 8, 10, and 15 after
HEL3X immunization. (D) Ratio of CD273+ MBCs to GC B cells at days 8, 10, and 15 after HEL3X immunization. (E) Frequency of Y53D mutations within splenic
IgG1+ GC B cells at day 8 (d8; left) and day 15 (right) after HEL3X immunization; the number of analyzed IgH sequences is shown inside the circle. (F) Frequency
of splenic IgG1+ GC B cells carrying the specified number of amino acid substitutions, analyzed at day 15 after HEL3X immunization. (G) Frequency of nucleotide
substitutions across the IgH V-region of SWHEL within splenic IgG1+ GC B cells at day 15 after HEL3X immunization. (H) Frequency of Y53D mutations within
splenic IgG1+ CD273+ MBCs at day 8 (left) and day 15 (right) after HEL3X immunization, number of analyzed IgH sequences is shown inside the circle.
(I) Frequency of splenic IgG1+ CD273+ MBCs cells carrying the specified number of amino acid substitutions, analyzed at day 15 after HEL3X immunization.
(J) Frequency of nucleotide substitutions across the IgH V-region of SWHEL within splenic IgG1+ CD273+ MBCs at day 15 after HEL3X immunization. (B–D)Mean
and SEM. *, P ≤ 0.05, **, P ≤ 0.01, ***, P ≤ 0.001 (unpaired two-tailed Student’s t test). Data are representative of three (B–D) independent experiments and
cumulative analysis of five mice per genotype per time point (E–J). ns, not significant.
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MycVDSWHEL MBCs (average, 2.3/sequence) compared with
MycWTSWHEL control (average, 4.8/sequence; Fig. 7 I; and Fig.
S4, E–G). Nevertheless, the vast majority of MycVDSWHELMBCs
(∼90%) displayed a somatically mutated BCR (Fig. 7 J), further
demonstrating that the observed increase inMBC differentiation
when MYC–MIZ1 complexes are absent occurs primarily
through a GC-dependent path. To investigate if the absence of
MYC–MIZ1 complexes altered antigen affinity of the PC pool, we
evaluated the binding of IgG1 antibodies in the serum of mice to
HEL3X at days 8 and 15 after immunization (Fig. S4 I). No sig-
nificant differences were found between genotypes, indicating
that the absence of MYC–MIZ1 complexes primarily impacts the
antigen affinity of the MBC pool. In summary, the absence of
MYC–MIZ1 complexes had a lasting impact in the MBC pool by
increasing its size and decreasing its affinity for the antigen.
MYC–MIZ1 complexes restrict MBC differentiation when
affinity-based selection is absent
LZ B cells bearing BCRs with lower antigen affinity are favored
to differentiate intoMBCs (Shinnakasu et al., 2016). Therefore, it
was possible that increased MBC differentiation in MycVD was
primarily the consequence of the transitory delay in GC B cell
affinity maturation in these mice. To test this hypothesis, we
used the SWHEL system and immunized recipient mice with
HEL, for which BCR affinity is very high (2 × 1010M−1; Paus et al.,
2006), effectively curtailing antigen affinity–based selection
(Fig. 8 A). Similar to the results using HEL3X immunization
(Fig. 7, A–D), the fraction of GC B cells was reduced within
MycVDSWHEL B cells, whereas the fraction of CD273+ MBCs was
increased, compared with MycWTSWHEL at all time points of
analysis (days 8 and 15; Fig. 8, B–D). We also performed an ex-
periment using mice deficient for the enzyme Aicda that is
critically required for somatic hypermutation and class-switch
recombination (Muramatsu et al., 2000). Aicda-deficient MycVD,
similarly to MycVD (Fig. 3), displayed a significant reduction in
the fraction of GC B cells compared with mice with Aicda defi-
ciency alone (Fig. S5, A and B). We also observed that LZ B cells
of Aicda-deficientMycVDwere impaired in cell cycle engagement
compared with Aicda-deficient mice, whereas the fraction of DZ
B cells engaged in cell cycle was not different between genotypes
(Fig. S5 C). Lastly, Aicda-deficient MycVD displayed a signifi-
cantly increased fraction of MBCs compared with mice with
Aicda deficiency alone (Fig. S5, D and E). We concluded that
MYC–MIZ1 complexes in LZ MYC+ cells restricted MBC differ-
entiation even when affinity-based selection was absent.
Discussion
MBCs are key for long-term protection from reinfection. How-
ever, the mechanisms underlying MBC differentiation are un-
clear. Here, we found that LZMYC+ cells mostly coexpressed the
transcription activators MYC and MIZ1. Complexes formed by
MYC and MIZ1 in these cells were required for repression of
MIZ1 target genes, effective cell cycle engagement of LZ B cells,
GC expansion, and PC formation. Notably, most of the MIZ1
target genes repressed by MYC–MIZ1 complexes were enriched
in MBCs, and the absence of MYC–MIZ1 complexes increased
MBC differentiation. Whether these events are interdependent
or independent, the first suggesting that restriction of MBC
differentiation in LZ MYC+ cells is required for effective GC
expansion and PC formation, remains to be determined. The
signals driving MIZ1 expression in LZ MYC+ cells also need
further investigation, because in contrast to MYC (Luo et al.,
2018), ex vivo BCR and CD40 coengagement was not sufficient
to induce MIZ1 in GC B cells. Further, the discrepancy between
Miz1 gene and protein expression argues for a tight regulation at
the posttranscriptional level. HUWE1 is an E3 ubiquitin ligase
that ubiquitinates MIZ1, triggering its proteasomal degradation
(Yang et al., 2010). However, previous analysis of HUWE1-
deficient mice suggest a limited function for this E3 ubiquitin
ligase in the GC reaction (Hao et al., 2012).
MYC–MIZ1 complexes were not equally required in all LZ
MYC+ cells, given that apparently a fraction entered cell cycle
normally. These data and of others (Ise et al., 2018) highlight the
need to investigate populational diversity within LZ MYC+ cells.
Figure 8. MYC–MIZ1 complexes restrict MBC differentiation in the ab-
sence of affinity-based selection. (A) Experimental design. (B) Kinetics of
GC B cells within splenic CD45.2+ donor cells at days 8 and 15 after HEL
immunization. (C) Kinetics of CD273+ MBCs within splenic CD45.2+ donor
cells at days 8 and 15 after HEL immunization. (D) Ratio of CD273+ MBCs to
GC B cells at days 8 and 15 after HEL immunization. (B–D)Mean and SEM. *,
P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 (unpaired two-tailed Student’s t test).
Data are representative of three (B–D) independent experiments and of the
cumulative analysis of five mice per genotype per time point.
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We also observed that cellular proliferation of activated B cells
in vitro was mostly unimpaired. Thus it is possible that MYC–
MIZ1 complexes are primarily required at specific B cell stages
and/or to counteract autocrine and/or paracrine (i.e., microen-
vironmental) antiproliferative signals (van Riggelen et al., 2010).
Most of the identified MIZ1 target genes up-regulated in the
absence of MYC–MIZ1 complexes were enriched in MBCs. Al-
though for many a function in B cells is unknown, for others
(namely Arhgef1, Gadd45g, Sh2b3, and Map2k7), tumor-
suppressive and/or antiproliferative activity was described (Lu
et al., 2001; Lv et al., 2017; Muppidi et al., 2014; Perez-Garcia
et al., 2013; Thalheimer et al., 2014). This knowledge is in
agreement withwork demonstrating that quiescent B cells in the
LZ are enriched for MBC precursors (Laidlaw et al., 2017; Suan
et al., 2017; Wang et al., 2017). Thus, MIZ1 transcriptional ac-
tivity may promote a quiescent state, which in turn permits
MBC differentiation. Such activity is restrained by MYC–MIZ1
complexes in LZ MYC+ cells. Whether MIZ1 transcriptional ac-
tivity is itself required for MBC differentiation needs further
investigation.
The finding that MIZ1 targets genes with B cell tumor sup-
pressor and/or antiproliferative function may be relevant for GC
B cell lymphomagenesis. It is tempting to speculate that inter-
ference with MBC differentiation could be oncogenic, similar to
what we and others demonstrated for PC differentiation (Calado
et al., 2010; Mandelbaum et al., 2010; Zhang et al., 2015).
In cancer, Cdkn1a is a well-characterized target of MYC–MIZ1
complexes (Herold et al., 2002; Walz et al., 2014). However,
Cdkn1a expression was unchanged in LZ B cells in the absence of
MYC–MIZ1 complexes. Previous work showed that BCL6 can
form a transcriptional repressor complex with MIZ1 that re-
presses CDKN1A expression in GC-derived lymphoma cell lines
(Basso and Dalla-Favera, 2010; Phan et al., 2005). Also, others
have also shown that EZH2 is required in GC B cells for re-
pression of Cdkn1a expression (Be´guelin et al., 2017). Thus, it is
possible that redundancy in the regulation of Cdkn1a expression
exists in GC B cells. In contrast, we found increased expression
of Cdkn1b in the absence of MYC–MIZ1 complexes. However, and
although our analysis and that of others have not identified
Cdkn1b as a direct MIZ1 target (Walz et al., 2014), this has been
suggested by other studies (Basu et al., 2009; Yang et al., 2001),
urging further investigation.
LZ B cells with high Bach2 expression are favored to differ-
entiate into MBCs (Shinnakasu et al., 2016). However, Bach2
expression was not altered in the absence of MYC–MIZ1 com-
plexes. Bach2 expression is inversely correlated to the strength
of T cell help (Shinnakasu et al., 2016). On the contrary, Myc is
induced upon positive selection downstream of T cell help (Luo
et al., 2018), and MYC levels were not altered by the absence of
MYC–MIZ1 complexes, suggesting that T cell help was not af-
fected. As a consequence, changes in Bach2 expression levels
would not be expected in the absence of MYC–MIZ1 complexes.
This does not contradict the role of Bach2 in the regulation of
MBC differentiation (Shinnakasu et al., 2016). First, Bach2 may
be required for MBC differentiation of a different LZ B cell
subset; second, we found that MYC–MIZ1 complexes repressed
the expression of the gene encoding the MAFK transcription
factor, with which BACH2 is bound at most target genes (Huang
et al., 2014; Oyake et al., 1996). Thus, given that strong T cell help
reduces Bach2 expression but does not extinguish it (Shinnakasu
et al., 2016), increased Mafk expression in the absence of
MYC–MIZ1 complexes could favor MBC differentiation.
Increased MBC differentiation, together with impaired GC
B cell expansion, was also found when LZ B cells cannot sense
IL21 and when LZ to DZ migration is abrogated by impaired
CXCR4 signaling (Bannard et al., 2013; Barinov et al., 2017;
Linterman et al., 2010; Zotos et al., 2010). In both scenarios,
antigen affinity was reduced, possibly favoring MBC differen-
tiation (Shinnakasu et al., 2016; Weisel et al., 2016). The absence
ofMYC–MIZ1 complexes led only to a transient delay in GC B cell
affinity. Thus, and although we cannot exclude a contribution of
this phenomenon toward increased MBC differentiation, we
found that MYC–MIZ1 complexes restricted MBC differentiation
even when affinity-based selection was absent. The MBC phe-
notype in IL21/IL21R deficiency was attributed to a GC-
independent path given that most MBCs had unmutated BCRs,
whereas for CXCR4 deficiency, the involvement of GCs was
suggested (Bannard et al., 2013; Linterman et al., 2010; Zotos
et al., 2010). The latter conclusion was based on the detection
of CD73 expression and MBC BrdU incorporation in pulse-chase
experiments (Bannard et al., 2013). We found that increased
MBC differentiation in the absence of MYC–MIZ1 complexes
occurred primarily through a GC-dependent path: (1) MYC–
MIZ1 complexes were required for GC expansion rather than
formation; (2) an increased number of EdU+ MBCs was formed
during critical time points of GC expansion; (3) the fraction of
IgG1+ CD73+ MBCs and LZ MBC precursors (CCR6+ LZ B cells)
was increased in MycVD compared with MycWT; and (4) the vast
majority (∼90%) of MBCs in MycVD display somatically
mutated BCRs.
Our work uncovered that MYC–MIZ1 complexes in LZ MYC+
cells are required for effective GC expansion and PC formation
and to restrict MBC differentiation. Until now, a physiological
function for MYC–MIZ1 complexes was unknown (Wiese et al.,
2013). MIZ1, similarly to MYC, is required for early B and T cell
development; however, these functions were shown to be in-
dependent of MYC–MIZ1 complexes (Douglas et al., 2001; Kosan
et al., 2010; Saba et al., 2011; Vallespinós et al., 2011). MIZ1 ho-
mologues and the conservation of a valine in position 394 in
MYC, critical for the interaction with MIZ1, are found only in
vertebrates (Conacci-Sorrell et al., 2014). Thus, compared with
other MYC network members, like MAX and MXD proteins,
MYC–MIZ1 complexes are a late addition in evolution (Conacci-
Sorrell et al., 2014). Interestingly, such evolutionary timeframe
is similar to that of AICDA (Conticello et al., 2005).
MYC–MIZ1 complexes per se are not essential for life (Wiese
et al., 2013). As a consequence, this protein complex is a viable
candidate for intervention in cancer and vaccination. With re-
spect to the latter, an increased MBC pool size with lower af-
finity for the primary immunizing antigen, as observed in the
absence ofMYC–MIZ1 complexes, may permit the recognition of
similar but different antigens and further affinity maturation
(Bannard and Cyster, 2017; Inoue et al., 2018; McHeyzer-
Williams et al., 2015; Mesin et al., 2016; Takahashi and Kelsoe,
Toboso-Navasa et al. Journal of Experimental Medicine 11 of 17
Restriction of memory B cell differentiation https://doi.org/10.1084/jem.20191933
2017; Tas et al., 2016). This could be important in vaccination for
protection against pathogenic substrains and evolved mutants
(Inoue et al., 2018; Victora and Wilson, 2015). Thus, inter-
ventions that modulate the activity of MYC–MIZ1 complexes
may tailor the GC response to meet individual humoral memory
requirements for infection control and prevention.
Materials and methods
Mice
MycVD, Cdkn1a KO, AID-Cre-ERT2, and the transgenic SWHEL
allelic BCR systemmouse strains have been previously described
(Brugarolas et al., 1995; Calado et al., 2012; Casola et al., 2006; de
Alboran et al., 2001; Dogan et al., 2009; Phan et al., 2003; Saba
et al., 2011). Mice were maintained on the C57BL/6 background
and bred at the Francis Crick Institute biological resources fa-
cility under specific pathogen–free conditions. Animal experi-
ments were performed in accordance with national and
institutional guidelines for animal care and approved by The
Francis Crick Institute biological resources facility strategic
oversight committee (incorporating the Animal Welfare and
Ethical Review Body) and by the Home Office, UK.
Immunization, adoptive transfers, and in vivo treatments
For T cell–dependent immunization, 8- to 12-wk-old mice were
injected i.v. with 109 defibrinated SRBCs (TCS Bioscience) in
PBS. EdU (Invitrogen) was dissolved in sterile PBS (5mg/ml); for
proliferation studies, 1 mg in a volume of 200 µl was injected i.p.
3 h before analysis; for the assessment of the kinetics of the
formation ofMBCs, 1.5 mg in a volume of 300 µl was injected i.p.
every 12 h for 3 d (protocol adapted from Weisel et al., 2016).
Adoptive transfers were performed into CD45.1+ or CD45.1+/
CD45.2+ congenic mice. Briefly, 3 × 104 HEL-binding B cells were
injected i.v. into congenic recipients, followed by i.v. immuni-
zation the next day with 2 × 108 SRBCs conjugated to a specific
recombinant HEL protein. SRBCs in Alsever’s (TCS Bioscience)
were conjugated to recombinant HEL (Sigma) or HEL3X (R.
Brink) with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
hydrochloride (Sigma) as previously described (Goodnow et al.,
1988). CD45.2+ splenic B cells from SWHEL donor mice were
purified by CD43 (Ly-48) MicroBeads (Miltenyi Biotec) depletion.
For analyses and cell FACS sorting, CD45.2+ donor splenocytes
were enriched by CD45.1-negative selection using anti-mouse bi-
otinylated CD45.1 antibody (clone A20; eBioscience) and Anti-
Biotin MicroBeads (Miltenyi Biotec).
Histology, immunohistochemistry, and immunofluorescence
Spleens were fixed with 10% neutral buffered formalin (Thermo
Fisher) and embedded in paraffin. Sections were stained with
hematoxylin (Sigma) and biotinylated peanut agglutinin (Vec-
tor). Images were acquired with Zeiss Axio Scan.Z1 Slide Scan-
ner and visualized with Photoshop (v12.1; Adobe). ImageJ
(v2.0.0) was used to quantify GC B cell area and number of GCs
per spleen section. For immunofluorescence, spleens were em-
bedded in optimum cutting temperature compound (Sakura)
and flash frozen in liquid nitrogen. 8- to 30-µM tissue sections
were cut on an OTF5000 cryostat (Bright Instruments), fixed in
4% paraformaldehyde (Thermo Fisher), permeabilized and
blocked in PBS with 0.3% Triton X-100 (Sigma) and 10% normal
goat serum (Sigma). Samples were stained with antibodies in
PBS containing 0.3% Triton X-100 with 1% bovine serum albu-
min (Thermo Fisher). Every incubation was followed by three
washes with PBS. To prevent cross-reactivity, samples were
blocked with PBS containing 10% normal rabbit serum (Sigma).
Images were acquired with a Leica Sp5 confocal microscope,
using sequential acquisition between frames with 405-, 488-,
555-, and 647-nm laser excitations. Images were analyzed with
Imaris software (Bitplane); cells were automatically identified
by the software based on nuclear Hoechst 33342 staining.
Antibodies
The following antibodies were used: rabbit anti-mouse caspase
3, clone C92-605 (BD Biosciences); rat anti-mouse CD19, clone
6D5 (BioLegend); rat anti-mouse CD23, clone B3B4 (BioLegend);
rat anti-mouse CD35, clone 8C12 (BD Biosciences); rat anti-
mouse CD38, clone 90 (BioLegend); rat anti-mouse CD45R/
B220, clone RA3-6B2 (BioLegend); mouse anti-mouse CD45.1,
clone A20 (eBioscience); mouse anti-mouse CD45.2, clone 104
(BD Biosciences); rat anti-mouse CD73, clone TY/23 (BD Bio-
sciences); rat anti-mouse CD86, clone GL1 (BioLegend); rat anti-
mouse CD93 (AA.1), clone AA4.1 (eBioscience); Armenian hamster
anti-mouse CD95 (FAS), clone Jo2 (BD Biosciences); rat anti-mouse
CD138 (Syndecan-1), clone 281–2 (BioLegend); rat anti-mouse
CD184 (CXCR4), clone 2B11 (eBioscience); rat anti-mouse CD273
(PD-L2), clone TY25 (BioLegend); rat anti-mouse IgD, clone 11-
26c.2a (BD Biosciences); rat anti-mouse IgG1, clone A85-1 (BD
Biosciences); rat anti-mouse IgM, clone II/41 (BD Biosciences);
Armenian hamster anti-mouse PD1(CD279), clone J43 (eBioscience);
rat anti-mouse CXCR5(CD185), clone (SPRCL5); rat anti-mouse CD4,
Clone (GK1.5); Armenian hamster anti-mouse CD3, clone (145-2C11);
Armenian hamster anti-mouse CD80(B7-1), clone (16-10A1); rat anti-
mouse CD21/CD35(CR2/CR1), clone (7E9); mouse anti-HEL, clone
HyHEL9 (R. Brink); rabbit anti-Myc N-262 (Santa Cruz); rabbit anti-
Myc, clone Y69 (Abcam); rabbit anti-Zbtb17 (Sigma); goat anti-rabbit
IgG (H+L; Molecular Probes), fluorochrome-labeled Streptavidin
(BioLegend, eBioscience, and BD Biosciences); biotinylated peanut
agglutinin (Vector); and IgG from rabbit serum (Sigma).
In vitro cell stimulation and transduction
Splenic naive B cells were purified by CD43 depletion (Miltenyi).
GC B cells were purified as previously described (Luo et al.,
2018). Naive and GC B cells were cultured in vitro in the pres-
ence of 10 µg/ml (anti-IgM+ anti-IgG; Jackson ImmunoResearch)
and/or 20 µg/ml anti-CD40 antibody (FGK45; Bio X Cell) with or
without 25 ng/ml IL-4. For cell proliferation studies, naive B cells
were stained with CellTrace Violet (Thermo Fisher) according to
the manufacturer’s protocol. HEK293T cells were transiently
transduced with a MIZ1-IRES-GFP expressing vector or GFP
control (VectorBuilder) using Lipofectamine (Invitrogen). Cells
were analyzed 48 h after transduction.
Flow cytometry and ELISA
Single-cell suspensions of spleen were prepared in FACS buffer
(2% FBS and 2 mM EDTA, in PBS; Gibco) and treated with Gey’s
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solution for erythrocyte lysis. Single-cell suspensions were
stained with antibodies. The use of biotinylated antibodies was
followed by incubation with fluorochrome labeled streptavidin
(1/200 dilution). For the analyses of SWHEL mice, HEL-binding
cells were stained with 50 ng/ml HEL (Sigma) followed by
HyHEL9-A647 (R. Brink). Dead cells were excluded using Zom-
bie NIR Fixable Viability Kit (BioLegend). For detection of EdU
incorporation, cells were fixed for 15 min at room temperature
in 4% paraformaldehyde (Thermo Fisher) after surface marker
and viability dye staining. Fixation was followed by Click-iT EdU
A647 flow cytometry assay kit or Click-iT Plus EdU Alexa Fluor
647 flow cytometry assay kit (Life Technologies) as indicated by
supplier. For the detection of cleaved caspase-3, samples were
fixed for 15 min at room temperature in 4% paraformaldehyde
(Thermo Fisher) after surface marker and viability dye staining,
followed by intracellular staining with BD Cytofix/Cytoperm
staining kit (BD Biosciences), as per manufacturer’s specifica-
tions. The detection of the transcription factor was performed
after surface marker and viability dye staining with True-
Nuclear Transcription Factor Buffer Set (BioLegend), following
supplier’s instructions. To prevent cross-reactivity, samples
were blocked with 10% normal rabbit serum. Samples were
acquired on an LSR-Fortessa (BD Biosciences) with FACS-Diva
software (BD Biosciences), and data were analyzed with FlowJo
software (v10.3; Tree Star). MBCs were FACS purified using the
following antibody panel: CD273+CD138neg B220+ CD19+ CD38high
IgDlow. Cell populations were defined by the following surface
markers: LZ GC B cells (B220+ CD19+ CD38low CD95high CXCR4low
CD86high), DZ GC B cells (B220+ CD19+ CD38low CD95high
CXCR4high CD86low), PCs (CD19low CD138+), and IgM+ and IgG1+
MBCs (B220+ CD19+ CD38high IgDlow CD273+); FO B cells
(AA4.1neg B220+ CD19+ CD38high IgD+ CD21high CD23high). Anti-
HEL3X IgG1 antibodies in sera were analyzed by ELISA as pre-
viously described (Phan et al., 2003, 2006).
IgH somatic mutation analysis
IgG1+ CD273+ HEL+ MBCs and IgG1+ HEL+ GC B cells from
SWHEL mice were sorted using a FACSAria III or FACSAria
Fusion (BD Biosciences). Cells were sorted into proteinase K
(Qiagen) containing buffer, as previously described (Brink et al.,
2015; Paus et al., 2006). The SWHEL Ig heavy-chain variable
region exon was PCR amplified using Taq DNA polymerase
(Thermo Fisher) with the primers 59-GTTGTAGCCTAAAAGATG
ATGGTG-39 and 59-GATAATCTGTCCTAAAGGCTCTGAG-39. The
primary PCR product was further amplified with the nested
primers 59-TTGTAGCCTAAAAGATGATGGTGTTAAGTC-39 and
59-CAACTTCTCTCAGCCGGCTC-39. Nested PCR product was
isolated using QIAquick Kit (Qiagen) and cloned into pGEM-T
Easy vector (Promega), as per the manufacturer’s instructions.
DH5α-competent bacteria (Life Technologies) were transformed
and single colonies were grown in 96 deep-well culture blocks
(Macherey-Nagel). DNA was extracted automatically with Bio-
robot Universal System (Qiagen) using Nucleospin 96 Plasmid
kits (Macherey-Nagel) and Sanger-sequenced with T7, SP6, M13
forward, and/or M13 reverse primers. Sequenced DNA was run
against VBASE2 database (Retter et al., 2005). Using HyHEL10
sequence as a reference, mature VDJ DNA sequences were
analyzed for the presence of somatic mutation events, and the
translated protein sequences were examined for amino acid
substitutions.
Gene expression analysis and ChIP-seq
For the gene expression profiling of MycWT and MycVD LZ GC
B cells (CD138neg, B220+, CD19+ CD38low, CD95high, CXCR4low
CD86high), MycWT MBCs (CD138neg, B220+, CD19+, AA4.1neg,
CD38+, IgDneg, CD273+), and MycWT FO B cells (AA4.1neg, B220+,
CD19+, CD38high, IgD+, CD21high, CD23high) were sorted by flow
cytometry at day 10 after immunization with SRBCs using a
FACSAria III or a FACSAria Fusion (BD Biosciences). Cells
were sorted in RTL Buffer Plus (Qiagen) containing 1%
β-mercaptoethanol (Sigma) and RNA purified using AllPrep
DNA/RNA Mini and Micro Kits (Qiagen) following the manu-
facturer’s instructions. RNA-seq was performed at the Francis
Crick Institute advanced sequencing facility. The RSEM package
(v1.3.0; Li and Dewey, 2011) and STAR (v2.5.2a; Dobin et al.,
2013) were used to align reads to the mouse mm10 tran-
scriptome, taken from Ensembl (vGRCm38) and available at the
University of California, Santa Cruz (https://genome.ucsc.edu).
For RSEM, all parameters were run as default using the
“–forward-prob 0” option for a strand-specific protocol. Differ-
ential expression analysis was performed with DESeq2 package
(v.1.12.4; Love et al., 2014) within R (v3.3.1; R Core Team, 2008;
http://www.R-project.org). Genes were considered to be dif-
ferential expressed if P < 0.05. GSEAwas performed using GSEA
software (v2.2.3) from the Broad Institute (Subramanian et al.,
2005). All analyses for RNA-seq–generated expression profiles
were done with ranked gene lists usingWald statistics. For ChIP,
splenic B cells from C57BL/6 mice were purified using anti-
mouse CD43 (Ly-48) MicroBeads (Miltenyi Biotec) depletion
and treated with Gey’s solution for erythrocyte lysis. Cells (2 ×
106 cells/ml) were cultured at 37°C (5% CO2) in DMEM supple-
mented GlutaMAX, nonessential amino acids, penicillin-
streptomycin, Hepes (Gibco), β-mercaptoethanol (Sigma), and
10% fetal bovine serum (Thermo Fisher) containing anti-IgM (5
µg/ml), CD40 ligand (0.5 µg/ml), and IL-4 (10 ng/ml) and har-
vested after 16 h. ChIP protocol was adapted from Seitz et al.
(2011). Briefly, cells in B cell media were fixed with formalde-
hyde (Sigma) at final concentration of 1% for 10 min at room
temperature. Glycine (Thermo Fisher) was added at a final
concentration of 0.125 M for 5 min at room temperature. Cells
were washed, pelleted, and stored at −80°C. After cell lysis, the
DNA of 35 × 106 cells was fragmented using BIORUPTOR 200
immersion sonicator under the following conditions: high
power, 30 s on, 30 s off (40 cycles). 100 μl of Pierce Protein A/G
Magnetic Beads were coupled to 10 µg of antibody or control
rabbit IgG antibody (Sigma). DNA was incubated with antibody-
coupled beads, and after uncoupling, DNA was purified with
NucleoSpin Gel and PCR Clean-up (Macheray-Nagel) following
the manufacturer’s protocol for SDS-rich samples using Buffer
NTB (Macheray-Nagel). Samples were sequenced on an Illumina
HiSeq2500 generating 100bp single ended reads. ChIP-seq reads
were aligned to the mouse mm10 genome assembly using
BWA version 0.7.15 (Li and Durbin, 2010) with a maximum
mismatch of two bases. Picard tools version 2.1.1 (http://www.
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broadinstitute.github.io/picard) was used to sort, mark dupli-
cates, and index the resulting alignment bam files. Files were
normalized, and tdf files (for visualization purposes) were cre-
ated using IGVtools version 2.3.75 software (http://www.
broadinstitute.org/igv) by extending reads by 50 bp and nor-
malizing to 10 million mapped reads per sample. Peaks were
called using the standard parameters by comparing im-
munoprecipitated samples to their respective input and/or IgG
controls using MACS version 2.1.1 (Zhang et al., 2008). Peaks
called by MACS were annotated using the “annotatepeaks”
function in the Homer version 4.8 software package (Heinz et al.,
2010). Common and unique peaks across experiments were de-
termined using a custom script. Datasets are available at the Na-
tional Center for Biotechnology Information Gene Expression
Omnibus under the following accession numbers: GSE129262,
GSE80669, GSE77319, GSE4142, GSE76502, GSE11961, andGSE98419.
Quantification and statistical analysis
Data were analyzed with unpaired two-tailed Student’s t test; a P
value of ≤0.05 was considered significant. Prism (v7 and v8,
GraphPad) was used for statistical analysis. A single asterisk (*)
in the graphs of figures represents a P value ≤0.05, double as-
terisks (**) a P value ≤0.01, triple asterisks (***) a P value ≤0.001,
and quadruple asterisks (****) a P value ≤0.0001; “ns” stands for
not statistically significant (i.e., a P value >0.05). Data in text and
figures are presented as median or mean ± SEM; each case is
indicated in the figure legends.
Online supplemental material
Fig. S1 showsMYC andMIZ1 expression in GC B cell populations,
the identified MYC–MIZ1 complex target genes, and PC and
CD4+ CXCR5+ PD1+ T cell populations in the absence of MYC–
MIZ1 complexes. Fig. S2 shows the gene expression of cell
cycle–related genes in the absence of MYC–MIZ1 complexes, the
characterization of MYC, MIZ1 in activated non-GC B cells, their
cell proliferation in the absence of MYC–MIZ1 complexes, and
MYC and MIZ1 expression in (pre-)GC B cells. Fig. S3 shows the
enrichment for genes up-regulated in MBCs in the absence of
MYC–MIZ1 complexes and MBC populations. Fig. S4 shows GC
and MBC affinity in the absence of MYC–MIZ1 complexes. Fig.
S5 shows that MYC–MIZ1 complexes restrict MBC differentia-
tion in the absence of Aicda.
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Figure S1. Gene expression and cellular populations in the absence of MYC–MIZ1 complexes. (A) RNA expression of Myc (left) and Miz1 (right) in wild-
type mice. DZ, DZ cells negative for Ap4; DZ Erly, DZ cells positive for Ap4; LZ MYCneg, LZ cells negative for MYC and AP4; LZ MYC+, LZ cells positive for MYC
and AP4; (Chou et al., 2016). (B) Representative flow cytometry of intracellular staining for MYC in splenic GC B cells of wild-type mice isolated at day 10 after
SRBC immunization (SRBCi) after 4 h (top), 12 h (middle), and 16 h (bottom) in vitro in media (Unst.) and in media in the presence of anti-Ig (anti-IgM + anti-IgG),
anti-CD40, anti-Ig + anti-CD40, and anti-Ig + anti-CD40 + IL-4. (C) Testing of intracellular staining for MIZ1 in HEK293T nontransduced (mock) and transiently
transduced with a plasmid expressing GFP (GFPpos and GFPneg) or a plasmid expressing MIZ1 and GFP as a bicistronic RNA (GFPpos MIZ1 and GFPneg MIZ1).
(D) Representative flow cytometry of intracellular staining for MIZ1 as in B. (E) Heatmap representation of RNA expression in LZ MYCneg and LZ MYC+ of wild-
type mice for genes bound in their promoters by MIZ1 and MYC “MYC↔MIZ1” as determined by ChIP-seq in mouse B cells. (F) Top left: Weight of the spleen of
MycWT and MycVD at day 10 after SRBC immunization. Top right: Fraction of splenic B lymphocytes of MycWT and MycVD at day 10 after SRBC immunization.
Bottom left: Absolute cell number of splenic B cells of MycWT and MycVD at day 10 after SRBC immunization. Bottom right: Ratio of IgG1+ GC B cells over IgM+
GC B at day 10 after SRBC immunization. (G) Representative flow cytometry gating strategy of PCs in MycWT and MycVD at day 10 after SRBC immunization
(SRBCi). spl, spleen. (H) Cumulative data for PCs, analyzed as in G at days 0, 5, and 10 after SRBC immunization. Top: Fraction of cells within lymphocytes.
Bottom: Absolute cell number. (I) Ratio of PCs over GC B cells. (J) Representative flow cytometry gating strategy for splenic CD4+ CXCR5+ PD1+ T cells (that
mostly contain Tfh cells) of MycWT and MycVD at day 10 after SRBC immunization. (K) Cumulative data for splenic CD4+ CXCR5+ PD1+ T cells. Top: Fraction
within CD4+ T cells, analyzed as in J. Bottom, ratio between CD4+ CXCR5+ PD1+ T cells over GC B cells. (L) Bar graph displaying GSEA of gene signature
“BASSO_CD40_SIGNALING_UP” and “SIG_CD40_PATHWAY” enrichment in the GEP of LZ B cells of MycWT and MycVD. FDR, false discovery rate; NES,
normalized enrichment score. Each symbol (F top left: MycWT n = 22, MycVD n = 20, F bottom left: MycWT n = 18, MycVD n = 17; F top right: MycWT n = 16, MycVD
n = 16, F bottom right: MycWT n = 12, MycVD n = 10; H and I: day 0MycWT n = 5, MycVD n = 4; day 5 MycWT n = 4, MycVD n = 4; day 10MycWT n = 14, MycVD n = 13;
K: MycWT n = 11, MycVD n = 10) represents an individual mouse; small horizontal lines show median, minimum, and maximum values. (A) ****, P ≤ 0.0001
(DEseq2). (F–K) *, P ≤ 0.05; **, P ≤ 0.01; ****, P ≤ 0.0001 (unpaired two-tailed Student’s t test). Data are representative of two (B–D, H, and I on days 0 and 5;
and K) and three (F, H, and I on day 10) independent experiments. ns, not significant.
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Figure S2. Cell cycle genes and proliferation in the absence of MYC–MIZ1 complexes. (A) Left: RNA expression of Ccnd2 (top) and Ccnd3 (bottom) derived
from RNA-seq analysis of FACS purified MycVD and MycWT LZ B cells at day 10 after SRBC immunization. Right: RNA expression of Ccnd2 (top) and Ccnd3
(bottom) in wild-type mice. DZ, DZ cells negative for Ap4; DZ Erly, DZ cells positive for Ap4; LZ MYCneg, LZ cells negative for MYC and AP4; LZ MYC+, LZ cells
positive for MYC and AP4 (Chou et al., 2016). (B) Left: RNA expression of CDK inhibitor genes Cdkn1a (top), Cdkn2a (middle), and Cdkn2b (bottom) derived as in
A. Right: RNA expression of CDK inhibitor genes Cdkn1a (top), Cdkn2a (middle), and Cdkn2b (bottom) in wild-type mice as described in A. (C) Left: RNA ex-
pression of Cdkn1b (top) derived as in A. Right: RNA expression of Cdkn1b (top) in wild-type mice as described in A. (D) Representative flow cytometry of
intracellular staining for MYC in splenic naive B cells of wild-type mice after 4 h (top) and 16 h (bottom) in vitro in media (Unst.) and in media with the presence
of anti-Ig (anti-IgM + anti-IgG), anti-CD40, anti-Ig + anti-CD40, and anti-Ig + anti-CD40 + IL4. (E) Representative flow cytometry of intracellular staining for
MIZ1 as in D. (F) Analysis of CellTrace Violet (CTV) dilution as a proxy of cell division of MycWT and MycVD naive B cells cultured for 96 h in vitro in media in the
presence of anti-Ig + anti-CD40 + IL4. Two of three experiments are shown. (G) Representative confocal immunofluorescence of an FDC area at day 4 after
SRBC immunization (SRBCi) in a wild-type C57BL/6 mouse (MIZ1, red; MYC, green; and FDC/CD35, cyan). White lines delineate the center of the FDC area.
Scale bar, 20 µm. Green stars identify MYC+MIZ1neg cells and orange start identifies a MIZ1+MYC+ cell. (H) Quantification of the fraction of MYC single positive
(MYC+MIZ1neg) and MYC, MIZ1 double positive (MIZ1+MYC+) cells within MYC positive (pre) GC B cells in FDC areas of spleen of C57BL/6 mice at day 4 after
SRBC immunization (D4 SRBCi). Each dot represents a mouse. (I) Analysis as in G. Each dot represents an FDC area. Each symbol (A–C: MycWT n = 3, MycVD n =
4) represents an individual mouse; small horizontal lines show median, minimum, and maximum values. (A–C) ***, P ≤ 0.001; ****, P ≤ 0.0001 (DEseq2).
(H and I) *, P ≤ 0.05; ***, P ≤ 0.001; ****, P ≤ 0.0001 (unpaired two-tailed Student’s t test). Data are representative of two (D and E) and three (F, H, and I)
independent experiments. ns, not significant.
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Figure S3. MBC-associated genes and populations in mice lacking MYC–MIZ1 complexes. (A) Bar graph displaying GSEA of GEP of LZ B cells of MycWT
andMycVD for gene signature “MBC vs. FO UP”; “GSE76502MBC vs. FO UP”; “GSE11961MBC vs. FO UP”; “MBC vs. FO DOWN”; “GSE76502MBC vs. FO DOWN”;
“GSE11961 MBC vs. FO DOWN”. FDR, false discovery rate; NES, normalized enrichment score. (B) Left: GSEA of GEP of MBC and FO of this work for “GSE11961
MBC vs. FO_UP” gene signature. Right: GSEA of GEP of MBC and FO for “GSE76502MBC vs. FO_UP” gene signature. (C) Left: RNA expression of Bach2 in MycVD
LZ B cells compared with MycWT LZ B cells, derived from RNA-seq analysis of FACS-purified cells at day 10 after SRBC immunization. Right: RNA expression of
Bach2. DZ, DZ cells negative for AP4; DZ Erly, DZ cells positive for AP4; LZ MYCneg, LZ cells negative for both MYC and AP4; LZ MYC+, LZ cells positive for both
MYC and AP4 (Chou et al., 2016). (D) Heatmap representation of RNA expression in LZ MYCneg and LZ MYC+ for genes bound in their promoters by MIZ1 and
MYC “MIZ1↔MYC” as determined by ChIP-seq in mouse B cells. Genes found significantly up-regulated in MBC vs. LZ B cells are presented within a red box.
(E) Representative flow cytometry using Fluorescence Minus One (FMO) controls for CD35 (left), CD80 (middle), and CD73 (right). (F) Representative flow
cytometry gating strategy for splenic IgG1+ MBCs of MycWT and MycVD at day 10 after SRBC immunization (SRBCi). spl, spleen. (G) Representative flow
cytometry for surface marker staining of splenic IgG1+ MBCs of MycWT and MycVD at day 10 after SRBC immunization (SRBCi). spl, spleen. (H) Cumulative data
for analysis as in G. Each symbol (C, left: MycWT n = 3, MycVD n = 4; H: MycWT n = 7, MycVD n = 5) represents an individual mouse, (C, left) small horizontal lines
show median, minimum, and maximum values; (C, right) mean and SEM. (C) ****, P ≤ 0.0001 (DEseq2). (H) *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 (unpaired
two-tailed Student’s t test). Data are representative of two (H) independent experiments. ns, not significant.
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Figure S4. Affinity maturation in the absence of MYC–MIZ1 complexes. (A) Quantification of amino acid substitutions in the IgH V-region of SWHEL in
IgG1+ GC B cells at day 8 (two left panels) and day 15 (two right panels) after HEL3X immunization of recipient mice transferred with MycWTSWHEL and
MycVDSWHEL B cells. (B) Frequency of GC B cells carrying the specified number of amino acid substitutions, analyzed at day 8 after HEL3X immunization.
(C) Average amino acid substitutions frequency across the IgH V-region of SWHEL in IgG1+ GC B cells at day 8 and day 15 after HEL3X immunization of recipient
mice transferred with MycWTSWHEL and MycVDSWHEL B cells. (D) Frequency of nucleotide substitutions across the IgH V-region of SWHEL within IgG1+ GC
B cells at day 8 after HEL3X immunization. (E) Quantification of the amino acid substitutions in the IgH V-region of SWHEL in IgG1+ CD273+ MBCs at day 8 (two
left panels) and day 15 (two right panels) after HEL3X immunization of recipient mice transferred with MycWTSWHEL and MycVDSWHEL B cells. (F) Frequency
of IgG1+ CD273+ MBCs carrying the specified number of amino acid substitutions, analyzed at day 8 after HEL3X immunization. (G) Average amino acid
substitutions frequency across the IgH V-region of SWHEL in IgG1+ CD273+ MBCs at days 8 and 15 after HEL3X immunization of recipient mice transferred with
MycWTSWHEL and MycVDSWHEL B cells. (H) Frequency of nucleotide substitutions across the IgH V-region of SWHEL within IgG1+ CD273+ MBCs at day 8 after
HEL3X immunization. (I) ELISA of serum of recipient mice transferred with MycWTSWHEL and MycVDSWHEL B cells to determine affinity maturation of IgG1
antibody response to HEL3X at days 8 and 15 after HEL3X immunization. Each symbol (C and G) represents an individual sequence; small horizontal lines show
the mean. Values represent mean and SEM (I). Cumulative analysis of five mice per genotype per time point. **, P ≤ 0.01; ****, P ≤ 0.0001 (unpaired two-tailed
Student’s t test). Green, CDR1; red, CDR2; blue, CDR3. av, average amino acid substitution per sequence; n, number of analyzed sequences.
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Figure S5. MYC–MIZ1 complexes restrict MBC differentiation in the absence Aicda. (A) Representative flow cytometry of splenic GC B cells of Aicda KO
and MycVD Aicda KO at day 10 after SRBC immunization (SRBCi). spl, spleen. (B) Cumulative data for fraction of splenic GC B cells in Aicda KO and MycVD Aicda
KO at day 10 after SRBC immunization. (C) Cumulative data of EdU incorporation in splenic DZ B cells (top) and LZ B cells (bottom) in Aicda KO and MycVD
Aicda KO at day 10 after SRBC immunization. (D) Representative flow cytometry gating strategy for splenic CD273+ MBCs of Aicda KO and MycVD Aicda KO at
day 10 after SRBC immunization (SRBCi). spl, spleen. (E) Cumulative data of splenic CD273+ MBCs in Aicda KO and MycVD Aicda KO at day 10 after SRBC
immunization. Top: Fraction of cells. Bottom: ratio of MBC to GC. Each symbol (B, C, and E: MycWT n = 9, MycVD n = 6) represents represent an individual
mouse; small horizontal lines indicate mean. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 (unpaired two-tailed Student’s t test). Data are representative of three
independent experiments. ns, not significant.
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